Shen, Li
Jhund, Pardeep S.
Anand, Inder S.
Carson, Peter E.
Desai, Akshay S.
Granger, Christopher B.
Køber, Lars
Komajda, Michel
McKelvie, Robert S.
Pfeffer, Marc A.
Solomon, Scott D.
Swedberg, Karl
Zile, Michael R.
McMurray, John J. V.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
https://doi.org/10.1007/s00392-020-01786-8
Documents that mention this clinical trial
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
https://doi.org/10.1007/s00392-020-01786-8
Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction
https://doi.org/10.1016/j.ahj.2011.09.007
Medical therapy for chronic heart failure
https://doi.org/10.1016/s0140-6736(11)61038-6
Essen Stroke Risk Score Predicts Clinical Outcomes in Heart Failure Patients with Preserved Ejection Fraction: Evidence from the TOPCAT trial
https://doi.org/10.1055/a-1932-8854
Documents that mention this clinical trial
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
https://doi.org/10.1007/s00392-020-01786-8
Funding for this research was provided by:
University of Glasgow
Article History
Received: 25 August 2020
Accepted: 24 November 2020
First Online: 10 December 2020
Compliance with ethical standards
:
: No author has a disclosure relevant to the subject of this manuscript.